compounding semaglutide fda Weight Loss — Restorative Compounding Pharmacy + Wellness FDA sets tirzepatide compounding deadlines

Better GLP-1 choice: Egg bites, Greek yogurt if available, protein drink, or a split protein box Frappuccinos and sweet coffee drinks These can add a lot of sugar and calories without much protein unless modified heavily

Controlled release of biologics for the treatment of type 2 diabetes

Sources Eli Lilly, "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial" (May 21, 2026) TRIUMPH-1 topline: 28.3% at 80 weeks, 30.3% at 104 weeks, 45.3% achieving 30%+ weight loss ClinicalTrials.gov NCT05929066 (TRIUMPH-1) Phase 3, status Completed, primary completion April 6, 2026 Eli Lilly Q4 2025 earnings call transcript (February 4, 2026) confirmed regulatory submission planned for 2026 Eli Lilly press releases and investor communications ClinicalTrials.gov (TRIUMPH program trial registrations) Jastreboff AM, et al

Serious adverse events (pancreatitis, gallstone formation, acute kidney injury) are rare but require immediate medical attention

Significant weight loss places additional demands on metabolic stability